X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with JUBILANT LIFE SCIENCES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA JUBILANT LIFE SCIENCES DISHMAN PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 25.1 26.2 95.7% View Chart
P/BV x 3.3 5.4 62.2% View Chart
Dividend Yield % 0.7 0.3 196.5%  

Financials

 DISHMAN PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
JUBILANT LIFE SCIENCES
Mar-14
DISHMAN PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs374187 200.4%   
Low Rs12965 198.0%   
Sales per share (Unadj.) Rs197.8364.3 54.3%  
Earnings per share (Unadj.) Rs21.26.8 309.8%  
Cash flow per share (Unadj.) Rs34.724.5 141.7%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.82.4 33.4%  
Book value per share (Unadj.) Rs179.9164.9 109.1%  
Shares outstanding (eoy) m80.69159.28 50.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.3 368.0%   
Avg P/E ratio x11.918.4 64.5%  
P/CF ratio (eoy) x7.25.1 141.0%  
Price / Book Value ratio x1.40.8 183.1%  
Dividend payout %9.443.8 21.5%   
Avg Mkt Cap Rs m20,30620,061 101.2%   
No. of employees `0000.86.2 13.4%   
Total wages/salary Rs m5,35511,052 48.5%   
Avg. sales/employee Rs Th19,252.79,383.0 205.2%   
Avg. wages/employee Rs Th6,459.51,786.9 361.5%   
Avg. net profit/employee Rs Th2,064.1176.3 1,170.8%   
INCOME DATA
Net Sales Rs m15,96158,034 27.5%  
Other income Rs m265191 139.2%   
Total revenues Rs m16,22658,224 27.9%   
Gross profit Rs m4,1035,786 70.9%  
Depreciation Rs m1,0912,812 38.8%   
Interest Rs m9443,237 29.2%   
Profit before tax Rs m2,334-72 -3,236.6%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m624696 89.5%   
Profit after tax Rs m1,7111,090 156.9%  
Gross profit margin %25.710.0 257.8%  
Effective tax rate %26.7-965.9 -2.8%   
Net profit margin %10.71.9 570.6%  
BALANCE SHEET DATA
Current assets Rs m11,01829,280 37.6%   
Current liabilities Rs m9,51738,912 24.5%   
Net working cap to sales %9.4-16.6 -56.7%  
Current ratio x1.20.8 153.9%  
Inventory Days Days11084 131.0%  
Debtors Days Days3551 68.7%  
Net fixed assets Rs m16,30455,712 29.3%   
Share capital Rs m161155 104.5%   
"Free" reserves Rs m12,90720,968 61.6%   
Net worth Rs m14,51626,265 55.3%   
Long term debt Rs m4,18917,169 24.4%   
Total assets Rs m29,80588,606 33.6%  
Interest coverage x3.51.0 355.0%   
Debt to equity ratio x0.30.7 44.2%  
Sales to assets ratio x0.50.7 81.8%   
Return on assets %8.94.9 182.4%  
Return on equity %11.84.2 283.9%  
Return on capital %17.511.6 151.6%  
Exports to sales %24.837.8 65.6%   
Imports to sales %3.716.5 22.7%   
Exports (fob) Rs m3,95621,933 18.0%   
Imports (cif) Rs m5969,567 6.2%   
Fx inflow Rs m4,95222,004 22.5%   
Fx outflow Rs m69711,749 5.9%   
Net fx Rs m4,25510,255 41.5%   
CASH FLOW
From Operations Rs m2,7868,026 34.7%  
From Investments Rs m-1,529-1,744 87.7%  
From Financial Activity Rs m-941-4,447 21.2%  
Net Cashflow Rs m3161,834 17.2%  

Share Holding

Indian Promoters % 61.4 45.6 134.6%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 3.7 8.7 42.5%  
FIIs % 12.7 21.2 59.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 21.1 104.7%  
Shareholders   46,261 23,815 194.3%  
Pledged promoter(s) holding % 35.8 15.9 225.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ORCHID PHARMA LTD  CIPLA  ABBOTT INDIA  ALEMBIC LTD  WYETH LTD  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS